BioCryst (BCRX) held its Q1 2026 earnings call on May 6, 2026 — nine days after Intellia's HAELO Phase 3 readout showed lonvo-z gene editing produced 87% attack reduction and 62% attack-free at six months in hereditary angioedema patients. The most material competitive event in HAE in years. We trawled the call to test whether management would address it.

What the call says

ORLADEYO Q1 2026 net revenue $148.3M, +21% YoY ex-EU. CEO Gayer reiterated the $1B peak sales target twice. Navenibart Phase 3 enrollment (ALPHA-ORBIT, ≈145 patients) completing by end of June 2026, ahead of schedule. EU licensing deal worth $70M upfront + up to $275M milestones with Neopharmed Gentili. Year six of the launch is operationally strong.

Across the full transcript — prepared remarks and Q&A — zero mentions of "Intellia," "lonvo-z," "gene editing," "HAELO," "CRISPR," "curative," or "one-time." This is the eighth consecutive BCRX earnings transcript with zero such mentions. Gayer's competitive framing splits the HAE market into two buckets ("oral preference vs injectable preference"), structurally excluding curative as a third bucket. No analyst on the call asked about HAELO either.

Cross-corpus check

We tested whether BCRX's silence is idiosyncratic or sectoral. KalVista (KALV): silent across three transcripts. Pharvaris (PHVS): silent in its 6-K filed May 12, 2026 — fifteen days after HAELO. Three of three HAE incumbents. NTLA reciprocates: across seven transcripts, NTLA never names BCRX, ORLADEYO, KALV, EKTERLY, PHVS, deucrictibant, Astria, or navenibart. Bidirectional silence.

The analyst coverage gap reinforces this. Of BCRX's five recurring sell-side analysts, only one (Maury Raycroft, Jefferies) cross-covers NTLA — and on the Q1 2026 BCRX call, he asked only about Netherton syndrome, not ORLADEYO. HAE specialists modeling BCRX/KALV/PHVS don't cover gene editing. Gene editing analysts don't cover HAE. No public forum integrates lonvo-z into incumbent peak revenue models.

What the market is doing

BCRX carries 14.8% short interest. Backing out enterprise value (≈$2.1B) against management's $1B ORLADEYO peak + $500M navenibart pipeline implies the market is already pricing roughly 45-55% revenue erosion versus the full narrative ($28/share). On evidence — HAELO Phase 3 hit, 54% physician prescribing intent (per NTLA market research, Q4 2025 call), BLA target mid-2027 — we estimate actual probability of meaningful ORLADEYO disruption at ≈35%.

The picture inverts on NTLA. With 39.3% short interest — extreme bearish positioning into a successful Phase 3 readout — market-implied probability of meaningful lonvo-z commercial success sits at ≈30-40%. Evidence-based estimate: 60-70%. Cohort relative performance reinforces the asymmetry: BCRX -2.8% trailing 1Y, KALV +136%, PHVS +91%. BCRX is the cohort name the market has already discounted.

Why the gap exists

The structural analyst coverage gap prevents the question from being asked. Sell-side reports flow to clients first; no HAE analyst has yet been asked by a client to model lonvo-z impact on incumbent peak revenue. The first bridge note — the activation moment — has not been written. We've assigned 35% probability to its publication by end of 2026.

Risks (ranked)

1. HAELO long-term durability data weakens or safety event — kills the NTLA thesis, validates incumbents
2. FDA delays BLA acceptance or issues CRL on lonvo-z — extends incumbent runway materially
3. BCRX Q2 print sustains commercial momentum — squeeze risk on shorts; year-6 prints likely visible weekly
4. Lonvo-z manufacturing scale-up constraints — 54% prescribing intent doesn't translate if capacity caps uptake
5. Lonvo-z pricing at parity to chronic LTPs over 5-year present value — compresses 54% physician intent
6. Surprise BCRX M&A bid — capture premium before thesis crystallizes

Catalysts

• NTLA Q1 2026 earnings (late May 2026) — first commercial framing update post-HAELO
• ALPHA-ORBIT enrollment completion (June 30, 2026)
• BCRX Q2 2026 call (August 2026) — continued silence test
• Lonvo-z BLA submission target H2 2026
• Sector-wide silence resolution (year-end 2026) — first incumbent acknowledgment or first sell-side bridge note
• Lonvo-z PDUFA mid-2027

What would change our mind

• Lonvo-z 24-month durability data fails or safety event
• BCRX or KALV reframes navenibart/EKTERLY as "bridge to gene editing" — preserves franchise narrative through transition
• Lonvo-z pricing leak at parity to chronic LTP 5-year present value
• HAE specialist initiates NTLA coverage — analyst gap closing
• BCRX strategic transaction (large pharma premium acquisition)

The trawl identified a real structural information asymmetry across HAE incumbent management, their analyst coverage, and cross-disciplinary sell-side modeling. The cleanest expression of the displacement thesis sits on NTLA's long side, not BCRX's short side, where the market has already partially adjusted.

Evidence

LR signal: 0.8 (mildly bearish on BCRX — confirms direction but the structural pattern has been partly priced; the actionable mispricing has migrated to NTLA-long).